Description
Stabilizes HIF from degradation in the proteasome and increases endogenous production of erythropoietin by inhibiting HIF-1α prolyl hydroxylase (IC50 = 0.49 µM); investigated in clinical trial for treatment of patients with anemia associated with chronic kidney disease and/or end-stage renal disease
Formal name: 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-3H-pyrazol-3-one
Synonyms: Molidustat
Molecular weight: 314.3
CAS: 1154028-82-6
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Prolyl Hydroxylation Enzymes||Research Area|Cell Biology|Proteolysis|Ubiquitin/Proteasome System||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors